Scholar Rock Holding ( (SRRK) ) just unveiled an announcement.
Scholar Rock reported its financial results for 2024, highlighting significant progress in its SMA program with the submission of a Biologics License Application for apitegromab, anticipated to launch in the U.S. in late 2025. The company also plans to expand its research into other neuromuscular disorders and cardiometabolic indications, supported by a strong financial position and recent public offering.
More about Scholar Rock Holding
Scholar Rock is a late-stage biopharmaceutical company focused on developing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role.
YTD Price Performance: -16.17%
Average Trading Volume: 919,399
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.47B
For a thorough assessment of SRRK stock, go to TipRanks’ Stock Analysis page.